Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis
Authors:
- Jan D. LunemannJLJan D. Lunemann
- Harald HegenHHHarald Hegen
- Luisa María VillarLVLuisa María Villar
- Konrad RejdakKonrad Rejdak
- Augusto Sao-AvilesASAugusto Sao-Aviles
- Pere Carbonell-MirabentPCPere Carbonell-Mirabent
- Jaume Sastre-GarrigaJSJaume Sastre-Garriga
- Neus Mongay-OchoaNMNeus Mongay-Ochoa
- Klaus BerekKBKlaus Berek
- Sergio Martínez-YélamosSMSergio Martínez-Yélamos
- Francisco Pérez-MirallesFPFrancisco Pérez-Miralles
- Ahmed AbdelhakAAAhmed Abdelhak
Open Access
- 1 July 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (4) , e200270
Abstract
The complement system is known to play a role in multiple sclerosis (MS) pathogenesis. However, its contribution to disease progression remains elusive. The study investigated the role of the complement system in disability progression of patients with primary progressive MS (PPMS). Sixty-eight patients with PPMS from 12 European MS centers were included in the study. Serum and CSF levels of a panel of complement components (CCs) were measured by multiplex enzyme-linked immunosorbent assay at a baseline time point (i.e., sampling). Mean (SD) follow-up time from baseline was 9.6 (4.8) years. Only one patient (1.5%) was treated during follow-up. Univariable and multivariable logistic regressions adjusted for age, sex, and albumin quotient were performed to assess the association between baseline CC levels and disability progression in short term (2 years), medium term (6 years), and long term (at the time of the last follow-up). In short term, CC played little or no role in disability progression. In medium term, an elevated serum C3a/C3 ratio was associated with a higher risk of disability progression (adjusted OR 2.30; 95% CI 1.17-6.03; p = 0.040). By contrast, increased CSF C1q levels were associated with a trend toward reduced risk of disability progression (adjusted OR 0.43; 95% CI 0.17-0.98; p = 0.054). Similarly, in long term, an elevated serum C3a/C3 ratio was associated with higher risk of disability progression (adjusted OR 1.81; 95% CI 1.09-3.40; p = 0.037), and increased CSF C1q levels predicted lower disability progression (adjusted OR 0.41; 95% CI 0.17-0.86; p = 0.025). Proteins involved in the activation of early complement cascades play a role in disability progression as risk (elevated serum C3a/C3 ratio) or protective (elevated CSF C1q) factors after 6 or more years of follow-up in patients with PPMS. The protective effects associated with C1q levels in CSF may be related to its neuroprotective and anti-inflammatory properties.Keywords
This publication has 39 references indexed in Scilit:
- The complement system as a biomarker of disease activity and response to treatment in multiple sclerosisImmunologic Research, 2017
- Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 functionClinical Immunology, 2016
- Complement regulator factor H in multiple sclerosisJournal of Cellular Biochemistry, 2011
- A Gradient of neuronal loss and meningeal inflammation in multiple sclerosisAnnals of Neurology, 2010
- The complement systemCell and tissue research, 2010
- Elevated plasma C4a levels in multiple sclerosis correlate with disease activityJournal of Neuroimmunology, 2010
- A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosisJournal of Neurology, 2008
- Homogeneity of active demyelinating lesions in established multiple sclerosisAnnals of Neurology, 2008
- The Classical Complement Cascade Mediates CNS Synapse EliminationCell, 2007
- Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complexJournal of the Neurological Sciences, 1987